Aurobindo Pharma's Eugia Pharma approved to manufacture Dasatinib Tablets, a bioequivalent to Bristol-Myers Squibb's Sprycel, ...

Benchmark NSE Nifty50 index ended up 161.71 points at 24328.95, while the BSE Sensex stood up 520.9 points at 80116.49. Among ...

The shares of the Mid-Cap company specializing in the development, manufacturing, and commercialization of generic ...

The up move in the stock came after the company arm Eugia Pharma Specialities, received final approval from USFDA to ...

Aurobindo Pharma's shares rose nearly 3% after its subsidiary, Eugia Pharma, received USFDA approval to market Dasatinib ...

Eugia Pharma, a subsidiary of Aurobindo Pharma, has secured final USFDA approval for manufacturing and marketing Dasatinib ...

Aurobindo Pharma rose 1.81% to Rs 1,209.60 after its wholly owned subsidiary, Eugia Pharma Specialities, received final approval from the U.S. Food and Drug Administration (USFDA) to manufacture and ...

Patent pool is a consortium of two or more patent-holders to promote a particular technology and share the market ...

India supplies over 45% of the generics and 15% of biosimilars used in the U.S., with major companies like Dr. Reddy’s, Aurobindo Pharma, Zydus Lifesciences, Sun Pharma, and Gland Pharma earning ...

Laurus Labs has announced that the company has received the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its API ...

Sun Pharma declined 0.93 per cent to Rs 1,689.35. About10 per cent of the Sun Pharma's US specialty revenues is formulated in ...

Aurobindo's manufacturing operations have once again landed the Indian drugmaker in hot water with the U.S. FDA. | ...